Evotec AG and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec’s technology platform and broad expertise in drug discovery and pre-clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-eternygen-enter-collaboration-to-identify-and-develop-novel-metabolic-disease-therapy-5205
Evotec receives first milestone in Roche biomarker collaboration
Evotec AG today announced the successful achievement of a milestone in its biomarker alliance with Roche. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-first-milestone-in-roche-biomarker-collaboration-5203
Evotec and Debiopharm Group(TM) to collaborate on development of new treatment for cancer
Evotec AG announced today a research collaboration and licensing deal with Debiopharm GroupTM Lausanne, Switzerland. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-debiopharm-grouptm-to-collaborate-on-development-of-new-treatment-for-cancer-5201
Evotec and Convergence form integrated pain alliance
Evotec AG today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-convergence-form-integrated-pain-alliance-5199
Evotec FY 2013: Execute on Innovate to create value
Evotec AG today announced its financial results for the fiscal year ended 31 December 2013, which are in line with the revised expectations communicated in the fourth quarter 2013. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fy-2013-execute-on-innovate-to-create-value-5197
Evotec acquires Bionamics GmbH to accelerate 'EVT Innovate' strategy
Evotec AG today announced the acquisition of the Germany-based Bionamics GmbH. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-acquires-bionamics-gmbh-to-accelerate-evt-innovate-strategy-5195
Evotec and Yale University to collaborate on cancer therapy
Evotec AG today announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-yale-university-to-collaborate-on-cancer-therapy-5191
Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than € 90 m cash for 2013 confirmed
Evotec AG today announced that it is adjusting its guidance regarding Group revenues. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-results-of-pre-clinical-studies-lead-to-reduction-in-revenues-nevertheless-profitable-and-more-than-eur-90-m-cash-for-2013-confirmed-5188
Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than EUR 90 m cash for 2013 confirmed
Evotec AG today announced that it is adjusting its guidance regarding Group revenues. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-ag-results-of-pre-clinical-studies-lead-to-reduction-in-revenues-nevertheless-profitable-and-more-than-eur-90-m-cash-for-2013-confirmed-5612
Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-pre-clinical-milestone-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5184